Who are low molecular weight heparin, 5-FU's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): nadroparin calcium-warfarin sequential anticoagulation, Low dose nadroparin, Intermediate dose nadroparin, LMWH+Folic acid, Klexane and ASA, LMWH (Fragmin, dalteparin).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-molecular-weight-heparin-5-fu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

low molecular weight heparin, 5-FU — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

low molecular weight heparin, 5-FU (low molecular weight heparin, 5-FU) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

phase 3 Anticoagulant Factor Xa, Thrombin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

low molecular weight heparin, 5-FU (low molecular weight heparin, 5-FU) — Shahid Beheshti University of Medical Sciences. Low molecular weight heparin works by inhibiting Factor Xa and thrombin, preventing blood clot formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
low molecular weight heparin, 5-FU TARGET	low molecular weight heparin, 5-FU	Shahid Beheshti University of Medical Sciences	phase 3	Anticoagulant	Factor Xa, Thrombin
nadroparin calcium-warfarin sequential anticoagulation	nadroparin calcium-warfarin sequential anticoagulation	Qilu Hospital of Shandong University	marketed	Anticoagulant combination (LMWH + vitamin K antagonist)	Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Low dose nadroparin	Low dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)
Intermediate dose nadroparin	Intermediate dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (via antithrombin III enhancement)
LMWH+Folic acid	LMWH+Folic acid	Omar Mamdouh Shaaban	marketed	Anticoagulant combination with vitamin supplement	Factor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component)
Klexane and ASA	Klexane and ASA	University of Helsinki	phase 3	Low-molecular-weight heparin + antiplatelet agent	Factor Xa, thrombin (enoxaparin); cyclooxygenase (aspirin)
LMWH (Fragmin, dalteparin)	LMWH (Fragmin, dalteparin)	McMaster University	phase 3	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa), Antithrombin III

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

Fresenius Kabi · 4 drugs in this class
University of Sao Paulo · 3 drugs in this class
Beijing Anzhen Hospital · 2 drugs in this class
San Filippo Neri General Hospital · 2 drugs in this class
Yong Seog Oh · 2 drugs in this class
CCRF Consulting Co., Ltd. · 1 drug in this class
Boston Scientific Corporation · 1 drug in this class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
Faculty Hospital Kralovske Vinohrady · 1 drug in this class
Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low molecular weight heparin, 5-FU — Competitive Intelligence Brief. https://druglandscape.com/ci/low-molecular-weight-heparin-5-fu. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab